Inovio Pharmaceuticals Inc(INO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:45 AM ET (Korea 9/11 20:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.18 | Insider Own | 0.47% | Shs Outstand | 103.4M | Perf Week | -5.88% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 44.1% | Insider Trans | - | Shs Float | 102.9M | Perf Month | 67.15% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.2 | Inst Own | 38.8% | Short Float | 19.4% | Perf Quarter | 17.43% |
| Income | -0.07B | P/S | - | EPS this Y | 57.83% | Inst Trans | 1.43% | Short Ratio | 5.69 | Perf Half Y | -24.26% |
| Sales | 0.00B | P/B | 24.11 | EPS next 5Y | 61.91% | ROA | -114.64% | Short Interest | 19.96M | Perf YTD | -26.44% |
| Book/sh | 0.05 | P/C | 3.61 | EPS past 3/5Y | 49.51% 32.44% | ROE | -409.87% | 52W High | -54.61% ($2.82) | Perf Year | -51.52% |
| Cash/sh | 0.35 | P/FCF | - | Sales past 3/5Y | -81.47% -61.18% | ROIC | -711.67% | 52W Low | 127.27% ($0.56) | Perf 3Y | -76.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 54.89% | Gross Margin | - | Volatility(W/M) | 7.92% 9.85% | Perf 5Y | -98.66% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -98.75% |
| Dividend Ex-Date | - | Quick Ratio | 1 | EPS Q/Q | 87.83% | Profit Margin | - | RSI (14) | 56.17 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1 | Sales Q/Q | - | SMA20 | 1.63% ($1.26) | Beta | 1.6 | Target Price | $3.17 |
| Payout | - | Debt/Eq | 1.83 | Earnings | 2026/8/12 | SMA50 | 17.35% ($1.09) | Rel Volume | 0.55 | Prev Close | $1.32 |
| Employees | 112 | LT Debt/Eq | 1.17 | EPS/Sales Surpr. | 67.7% - | SMA200 | -10.02% ($1.42) | Avg Volume(3M) | 3.51M | Price | $1.28 |
| IPO | 1998/12/8 | Option/Short | Yes/Yes | Trades | 5443 | Volume | 1,935,909 | Change | -3.03% |
Company
INO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Inovio Pharmaceuticals (INO) is a US clinical-stage biotechnology company developing DNA-based medicines. Using its proprietary electroporation delivery device, the company is researching immunotherapy candidates for HPV-related diseases, cancers, and infectious diseases. Commercial product revenue remains limited, and progress in its clinical pipeline is the key driver of the company's valuation.
Over the past 1 year, roughly in the middle
55% below its 1-year high.
INO has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +57.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -76.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 38.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GENZ 17MIt ranks #4 in the industry
Based on market cap of $132M.
INO $132M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is INO?
INO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INO?
The market cap of INO is approximately $132M, ranking 4,390 within its sector.
What is the 52-week high and low for INO?
INO has recorded a 52-week high of $2.82 and a low of $0.56.
